Nervi Bruno, Link Dan C, DiPersio John F
Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri 63110, USA.
J Cell Biochem. 2006 Oct 15;99(3):690-705. doi: 10.1002/jcb.21043.
Hematopoietic stem cell transplantation (HSCT) has become the standard of care for the treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute leukemias or lymphomas, multiple myeloma; and for some non-malignant diseases such as aplastic anemia and immunodeficient states. The hematopoietic stem cell (HSC) resides in the bone marrow (BM). A number of chemokines and cytokines have been shown in vivo and in clinical trials to enhance trafficking of HSC into the peripheral blood. This process, termed stem cell mobilization, results in the collection of HSC via apheresis for both autologous and allogeneic transplantation. Enhanced understanding of HSC biology, processes involved in HSC microenvironmental interactions and the critical ligands, receptors and cellular proteases involved in HSC homing and mobilization, with an emphasis on G-CSF induced HSC mobilization, form the basis of this review. We will describe the key features and dynamic processes involved in HSC mobilization and focus on the key ligand-receptor pairs including CXCR4/SDF1, VLA4/VCAM1, CD62L/PSGL, CD44/HA, and Kit/KL. In addition we will describe food and drug administration (FDA) approved and agents currently in clinical development for enhancing HSC mobilization and transplantation outcomes.
造血干细胞移植(HSCT)已成为治疗多种血液系统恶性肿瘤、化疗敏感的复发性急性白血病或淋巴瘤、多发性骨髓瘤的标准治疗方法;也用于治疗一些非恶性疾病,如再生障碍性贫血和免疫缺陷状态。造血干细胞(HSC)存在于骨髓(BM)中。在体内和临床试验中,多种趋化因子和细胞因子已被证明可增强HSC向外周血的迁移。这一过程称为干细胞动员,可通过单采术采集HSC用于自体和异体移植。对HSC生物学、HSC与微环境相互作用所涉及的过程以及HSC归巢和动员所涉及的关键配体、受体和细胞蛋白酶的深入理解,尤其是对粒细胞集落刺激因子(G-CSF)诱导的HSC动员的理解,构成了本综述的基础。我们将描述HSC动员所涉及的关键特征和动态过程,并重点关注关键的配体-受体对,包括CXCR4/SDF1、VLA4/VCAM1、CD62L/PSGL、CD44/HA和Kit/KL。此外,我们还将描述美国食品药品监督管理局(FDA)批准的以及目前正在临床开发中的用于增强HSC动员和移植效果的药物。